

Notice under Section 708A of the Corporations Act

This notice is given by **HeraMED Limited (ASX:HMD)** (Issuer or **Company**) under section 708A(5)(e) of the Corporations Act 2001 ("Act").

On 19 February 2020, the Issuer issued 500,000 Ordinary Fully Paid Shares at a deemed issue price of AU\$0.15 per share (the Securities) pursuant to Resolution 6 of the Notice of Extraordinary General Meeting lodged with the ASX on 20 January 2020 and approved by shareholders at that meeting on 19 February 2020.

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Issued Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and section 674 of the Act; and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
 - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
 - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
 - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
 - ii. the rights and liabilities attaching to the Securities.

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0) 8 6189 1155

E: stephen@hera-med.com

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilizes the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The company is revolutionizing the pregnancy experience by empowering personalized, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.